Tandem Diabetes Care Stock Net Income
| TNDM Stock | USD 37.01 0.65 1.79% |
Tandem Diabetes Care fundamentals help investors to digest information that contributes to Tandem Diabetes' financial success or failures. It also enables traders to predict the movement of Tandem Stock. The fundamental analysis module provides a way to measure Tandem Diabetes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tandem Diabetes stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -200.3 M | -190.3 M | |
| Net Loss | -200.3 M | -190.3 M | |
| Net Loss | -108.8 M | -114.2 M | |
| Net Loss | (3.09) | (3.24) | |
| Net Income Per E B T | 1.16 | 1.10 |
Tandem | Net Income |
Tandem Diabetes Care Company Net Income Analysis
Tandem Diabetes' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Tandem Diabetes Net Income | (222.61 M) |
Most of Tandem Diabetes' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tandem Diabetes Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tandem Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Tandem Diabetes is extremely important. It helps to project a fair market value of Tandem Stock properly, considering its historical fundamentals such as Net Income. Since Tandem Diabetes' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tandem Diabetes' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tandem Diabetes' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Tandem Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Tandem Diabetes Care reported net income of (222.61 Million). This is 165.23% lower than that of the Health Care Equipment & Supplies sector and 193.49% lower than that of the Health Care industry. The net income for all United States stocks is 138.99% higher than that of the company.
Tandem Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tandem Diabetes' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tandem Diabetes could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics of similar companies.Tandem Diabetes is currently under evaluation in net income category among its peers.
Tandem Diabetes ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tandem Diabetes' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tandem Diabetes' managers, analysts, and investors.Environmental | Governance | Social |
Tandem Diabetes Institutional Holders
Institutional Holdings refers to the ownership stake in Tandem Diabetes that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Tandem Diabetes' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Tandem Diabetes' value.| Shares | Millennium Management Llc | 2024-09-30 | 1.4 M | Stephens Inv Mgmt Group Llc | 2024-09-30 | 1.3 M | Park West Asset Management Llc | 2024-09-30 | 1.1 M | Divisadero Street Capital Management, Lp | 2024-09-30 | 1.1 M | First Light Asset Management, Llc | 2024-09-30 | 1 M | Chicago Capital, Llc | 2024-09-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 992.7 K | Next Century Growth Investors Llc | 2024-09-30 | 982.7 K | Hhg Plc | 2024-09-30 | 913.5 K | Blackrock Inc | 2024-09-30 | 11.1 M | Vanguard Group Inc | 2024-09-30 | 7.4 M |
Tandem Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.0969 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 2.43 B | ||||
| Shares Outstanding | 65.68 M | ||||
| Shares Owned By Insiders | 0.79 % | ||||
| Shares Owned By Institutions | 99.21 % | ||||
| Number Of Shares Shorted | 7.17 M | ||||
| Price To Earning | 494.25 X | ||||
| Price To Book | 10.23 X | ||||
| Price To Sales | 2.85 X | ||||
| Revenue | 747.72 M | ||||
| Gross Profit | 425.41 M | ||||
| EBITDA | (194.66 M) | ||||
| Net Income | (222.61 M) | ||||
| Cash And Equivalents | 608.73 M | ||||
| Cash Per Share | 9.47 X | ||||
| Total Debt | 415.67 M | ||||
| Debt To Equity | 1.00 % | ||||
| Current Ratio | 4.80 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (31.81 M) | ||||
| Short Ratio | 6.72 X | ||||
| Earnings Per Share | (1.94) X | ||||
| Target Price | 51.1 | ||||
| Number Of Employees | 2.4 K | ||||
| Beta | 1.37 | ||||
| Market Capitalization | 2.43 B | ||||
| Total Asset | 952.66 M | ||||
| Retained Earnings | (951.8 M) | ||||
| Working Capital | 552.73 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 26.52 M | ||||
| Net Asset | 952.66 M |
About Tandem Diabetes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Tandem Diabetes Piotroski F Score and Tandem Diabetes Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (1.94) | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.